Key result
CHAMPIONS score stratifies 1-year M-TEER mortality, while residual MR ≤1 cuts intermediate-risk deaths by ~15 percentage points.
Why the study?
Although mitral transcatheter edge-to-edge repair (M-TEER) is an established treatment for symptomatic mitral regurgitation at high surgical risk, a risk stratification tool to predict one-year mortality and evaluate how baseline risk modifies the prognostic impact of procedural success and residual MR was needed.
Does the CHAMPIONS risk score predict one-year mortality and identify interactions between baseline risk and procedural success in patients undergoing mitral transcatheter edge-to-edge repair?
Cohort (n=939)
Does the CHAMPIONS risk score predict one-year mortality and identify interactions between baseline risk and procedural success in patients undergoing mitral transcatheter edge-to-edge repair?
The CHAMPIONS score stratifies one-year mortality risk in M-TEER patients and identifies intermediate-risk patients as the primary group deriving a significant survival benefit from achieving residual MR ≤ 1.
Answers are grounded in this paper and cite their sources.
May support one-year mortality stratification after M-TEER; hypothesis-generating pending external validation and randomized confirmation.
Background Mitral transcatheter edge-to-edge repair (M-TEER) is an established treatment for symptomatic mitral regurgitation (MR) in patients at high surgical risk. This study aimed to develop a risk stratification tool to predict one year-mortality and to investigate how baseline risk modifies the prognostic impact of procedural success. Purpose To (1) develop the CHAMPIONS risk score for predicting one-year mortality after M-TEER and (2) evaluate the interaction between baseline risk and residual MR. Methods Score development followed a machine learning-guided approach. A random forest classifier was trained on 80% of the overall cohort (n=939). The remaining 20% served as an internal validation subset. The top 20 variables were selected for logistic regression. Regression coefficients were translated into a point-based score (0-14 points), with higher beta-coefficients corresponding to higher point allocations. The score incorporates nine routinely available parameters. Patients were categorized into low, intermediate and high-risk groups based on their total score. Results The CHAMPIONS score demonstrated moderate discrimination (AUC: 0.67) and excellent calibration (Hosmer-Lemeshow test: x2 = 0.41, p=0.995). One-year mortality rates increased stepwise across risk categories: low (7.6%), intermediate (16.7%) and high risk (30.9%) (log-rank p<0.001). A significant interaction was found between baseline risk and residual MR. Achieving residual MR ≤ 1 was associated with survival benefits primarily in the intermediate-risk group (mortality 10.4% vs 25.1%, p<0.001). Residual MR did not significantly change survival for patients in the low- or high-risk categories. Conclusion The CHAMPIONS score is a simple tool for pre-procedural risk stratification in M-TEER patients. It identifies intermediate-risk patients as the primary group were achieving residual MR ≤ 1 leads to a significant survival benefit. External validation is needed to confirm its generalizability and refine its predictive performance.
No takes yet. Share an insight, caveat, or question.
Stoeckl et al. (2026) conducted a cohort in Symptomatic mitral regurgitation undergoing mitral transcatheter edge-to-edge repair (M-TEER) (n=939). CHAMPIONS pre-procedural risk score and residual MR ≤ 1 vs. Residual MR > 1 and across low, intermediate, and high baseline risk categories was evaluated on One-year mortality (AUC 0.67, p=<0.001). The CHAMPIONS score stratified 1-year M-TEER mortality, with residual MR ≤1 reducing mortality in intermediate-risk patients.
Synapse has enriched 10 related papers. Consider them for comparative context: